Details of the Drug Combination

General Information of Drug Combination (ID: DCTDKUM)

Drug Combination Name
Bedaquiline Delamanid
Indication
Disease Entry Status REF
Tuberculosis Phase 2 [1]
Component Drugs Bedaquiline   DM3906J Delamanid   DMXE76K
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bedaquiline
Disease Entry ICD 11 Status REF
Drug-resistant tuberculosis N.A. Approved [2]
Multi-drug resistant tuberculosis MG52.00 Approved [3]
Pulmonary tuberculosis 1B10.Z Approved [2]
Bedaquiline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Proton pump (MycB Prop) TT19K0L A0A1Q4HQH4_9MYCO Modulator [6]
------------------------------------------------------------------------------------
Bedaquiline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Delamanid
Disease Entry ICD 11 Status REF
Multi-drug resistant tuberculosis MG52.00 Approved [4]
Mycobacterium infection 1B10-1B21 Phase 3 [5]
Delamanid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Cell membrane (Bact CM) TTXT4D5 NOUNIPROTAC Inhibitor [4]
------------------------------------------------------------------------------------
Delamanid Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05382312) Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
2 Bedaquiline FDA Label
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
5 ClinicalTrials.gov (NCT01424670) Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis. U.S. National Institutes of Health.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
8 Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76.